Capital Raising

Biosignals Diagnostics

Mission-driven company targeting un-met clinical needs

Mission-driven company targeting un-met clinical needs

x

INDUSTRY

Medical, Technology

RAISING

A$1.116M

PRE-MONEY VALUATION

A$8.9M

OFFER PRICE

A$0.171

Investment Highlights Company Overview Products & Services Transaction Overview Team

Transaction Summary

Biosignals Diagnostics

  • Raising A$1.116M

  • A$0.171 per share


Investment Highlights


  • Biosignal monitoring company

  • Prevent, diagnose, and change outcomes for heart disease & stroke

  • ECGme device provides cost effective & real time solutions

  • Precision Healthcare

Company Overview


  • Heart disease remains the biggest killer in the world

    death rates are estimated to double in the next 20 years

  • Biosignals Diagnostics provides solutions

    Several global markets offering tailored solutions based on unmet needs or improved standard of care

  • ISV partner agreement with Oracle

    signed on 5th April 2022

  • Demonstrations of the ECGme device

    completed across twelve private meetings at the AusMedtech2022 conference

Products & Services


Biosignals Diagnostics offers solutions that target unmet clinical needs or improved standard of care in heart disease, with verified customers and markets.

Biosignals Diagnostics is a biosignal monitoring company, that addresses heart disease problems by integrating biometric data from specially designed, easily used devices and other sources such as imaging and genetics.

Product Suite

slide-image
slide-image

ECGME

  • Small easy to use the device (the size of a credit card), fits in your pocket and when held with fingers on the sensors analyses real-time ECG signals
  • Point-in-time ECG snapshot configurable for up to 10 minutes monitoring duration
  • Converts to a 2 electrode 24hr on-body monitor for clinical use
  • A TGA-approved Class 2a medical device
  • Available July 2022

Transaction Overview


Raising A$1.116M at A$0.171 per share, with a pre-money valuation of A$8.9M,

6,521,739 shares on offer

image
Use of funds

20%ECGme Deployment

30%Platform Software Development

30%Marketing / Sales

20%3 Lead ECG3me Development

Team


  • Management
  • Richard Rendell

    Managing Director & Founder

    iconicon
  • Christopher Pendlebury

    Chief Science Officer

    iconicon
  • Hayden Pitout

    Chief Technical Officer

  • Kevin Hollingsworth

    Company Secretary

  • Lexie Qin

    Head of Product Engineering

  • Renee Ge

    AI & Data Sciences Engineering

  • Stephan G Foy – MB ChB MD

    Consulting Cardiologist & Clinical Advisor